With the 2025 ASCO Annual Meeting (ASCO25) wrapping up today, we highlighted some of the innovative studies presented on breast cancer research. The five-day conference, held from May 30 to June 3, was located in Chicago, Illinois. The annual event featured oncology experts from all around the world coming together to discuss the latest insights, share emerging technologies, and network with colleagues.
With so many research presentations at the event, we’ve created rundowns for breast cancer, hematologic malignancies, and melanoma to help you better browse through some of the exciting topics presented at ASCO25.
- Description: Current treatment de-escalation strategies in HER2+ early breast cancer aim to mitigate acute and late toxicities by reducing or omitting systemic chemotherapy. Researchers analyzed the outcomes and investigated predictors of survival in three randomized de-escalation trials investigating 12-week neoadjuvant treatments with and without systemic chemotherapy (paclitaxel, pac) in HER2+ eBC.
- Result: This pooled analysis demonstrates that de-escalation trials in HER2+ eBC are feasible and safe for patients. 12x weekly paclitaxel + HER2 blockade is an effective and well-tolerated regimen with excellent five-year survival. The favorable survival after pCR to sCTx-free NAT lays the groundwork for further de-escalation strategies.
- Description: The ASTRRA trial previously demonstrated that adding ovarian function suppression to tamoxifen showed consistent disease free survival benefit at eight-year follow-up analysis in premenopausal women with hormone-receptor-positive breast cancer who remain premenopausal or resume menstruation after chemotherapy. The study aimed to update the survival outcomes and identify patients most likely to benefit from ovarian function suppression to tailor clinical decision-making.
- Result: The study demonstrated the consistent benefit of adding ovarian function suppression for two years to tamoxifen in improving 10-year disease free survival. This approach may be beneficial, especially for those aged 40-45 years.
- Description: Our study aimed to determine if a pre-surgical window-of-opportunity intervention with conjugated estrogen/bazedoxifene in women with ductal carcinoma in situ had a protective effect on the duct epithelium and stroma of ductal carcinoma in situ lesions without impacting quality of life.
- Result: In this prospective randomized clinical trial, conjugated estrogen/bazedoxifene significantly reduced epithelial proliferation in estrogen receptor positive ductal carcinoma in situ with no impact on quality of life compared to placebo.
- Description: This real world analysis describes pt characteristics and outcomes among Black patients eligible for NATALEE and receiving endocrine therapy.
- Result: In a real world dataset of patients eligible for adjuvant ribociclib based on NATALEE inclusion criteria, Black patients had a higher recurrence risk and worse survival compared with White patients, underscoring the opportunity to improve outcomes and address racial disparities in Black patients with HR+/HER22 early breast cancer.
- Description: Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as a significant therapeutic advance in breast cancer treatment. However, concerns about therapy-related myeloid neoplasms, specifically myelodysplastic syndrome and acute myeloid leukemia, necessitate thorough investigation of their safety profile in real-world settings.
- Result: The researchers noted a significantly increased risk of therapy-related myeloid neoplasms with PARP inhibitor treatment compared to conventional chemotherapy, particularly in the context of previous platinum exposure in breast cancer patients.
- Description: Triple-negative breast cancer (TNBC) is associated with higher risk of recurrence and poorer survival rates than other breast cancer subtypes. For node-positive TNBC or tumors larger than 0.5 cm, chemotherapy is generally recommended. For stage I TNBC, the benefit from chemotherapy, the optimal regimen, and whether to administer it in the neoadjuvant versus adjuvant setting remain controversial.
- Result: Patients who received chemotherapy (adjuvantly or neoadjuvantly) had better 5-year recurrence-free survival compared with those treated with locoregional therapy only. Among patients receiving chemotherapy, 5-year recurrence-free survival was nearly identical regardless of whether chemotherapy was administered before or after surgery.
For a full list of abstracts, visit the official ASCO25 website.
Sign up for alerts and stay informed on the latest published guidelines and conference recaps.
Copyright © 2025 Guideline Central, all rights reserved.